ArticleCardiovascular and interventional radiology2019
Radioembolization with
Article in Cardiovascular and interventional radiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds.European journal of nuclear medicine and molecular imaging · 2022Guideline
- Reassessment of the lung dose limits for radioembolization.Nuclear medicine communications · 2021Pooled it
- Efficacy and evaluation of dose-response relationship of selective internal radiation therapy for the management of liver metastases in neuroendocrine neoplasia.European journal of nuclear medicine and molecular imaging · 2026Trial
- Yttrium-90 Selective Internal Radiation Therapy for Neuroendocrine Liver Metastases: An Institutional Case Series, Updated Systematic Review, and Meta-Analysis.Diagnostics (Basel, Switzerland) · 2025Article
- PRRT plus holmium-166-SIRT (HEPAR PLuS) versus PRRT-only in patients with metastatic neuroendocrine tumors: A propensity-score matched analysis.Journal of neuroendocrinology · 2025Article
- Eastern Canadian Gastrointestinal Cancer Consensus Conference 2024.Current oncology (Toronto, Ont.) · 2025Article
- Radioembolization for neuroendocrine tumors: procedure, application and clinical outcomes.Endocrine oncology (Bristol, England) · 2025Review
- Dose-effect relationships in neuroendocrine tumour liver metastases treated with [European journal of nuclear medicine and molecular imaging · 2024Article
- New frontiers in radioembolization.Therapeutic advances in medical oncology · 2024Review
- Clinically Translatable Phosphonated Silica Microspheres for Selective Internal Radiation Therapy of Hepatocellular Carcinoma.Small science · 2023Article
- SEOM-GETNE clinical guidelines for the diagnosis and treatment of gastroenteropancreatic and bronchial neuroendocrine neoplasms (NENs) (2022).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023Article
- Article
- Review
- Pancreatic neuroendocrine tumors: tailoring imaging to specific clinical scenarios.Abdominal radiology (New York) · 2023Review
- Diagnostic Management of Gastroenteropancreatic Neuroendocrine Neoplasms: Technique Optimization and Tips and Tricks for Radiologists.Tomography (Ann Arbor, Mich.) · 2023Review
- Using an Assumed Lung Mass Inaccurately Estimates the Lung Absorbed Dose in Patients Undergoing HepaticCardiovascular and interventional radiology · 2022Article
- The Evolving Role of Radioembolization in the Treatment of Neuroendocrine Liver Metastases.Cancers · 2022Review
- Apparent diffusion coefficients (ADC) in response assessment of transarterial radioembolization (TARE) for liver metastases of neuroendocrine tumors (NET): a feasibility study.Acta radiologica (Stockholm, Sweden : 1987) · 2022Article
- Lung Dose Measured on PostradioembolizationJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022Article
- Dose-response relationship after yttrium-90-radioembolization with glass microspheres in patients with neuroendocrine tumor liver metastases.European journal of nuclear medicine and molecular imaging · 2022Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeRadioembolization of liver metastases of neuroendocrine neoplasms (NEN) has shown promising results; however, the current literature is of limited quality. A large international, multicentre retrospective study was designed to address several shortcomings of the current literature. MATERIALS: 244 NEN patients with different NEN grades were included.
methodsPrimary outcome parameters were radiologic response 3 and 6 months after treatment according to RECIST 1.1 and mRECIST. Secondary outcome parameters included clinical response, clinical and biochemical toxicities.
resultsRadioembolization resulted in CR in 2%, PR in 14%, SD in 75% and PD 9% according to RECIST 1.1 and in CR in 8%, PR in 35%, SD in 48% and PD in 9% according to mRECIST. Objective response rates improved over time in 20% and 26% according to RECIST 1.1. and mRECIST, respectively. Most common new grade 3-4 biochemical toxicity was lymphocytopenia (6.7%). No unexpected clinical toxicities occurred. Radioembolization-specific complications occurred in < 4%. In symptomatic patients, improvement and resolution of symptoms occurred in 44% and 34%, respectively. Median overall survival from first radioembolization was 3.7, 2.7 and 0.7 years for G1, G2 and G3, respectively. Objective response is independent of NEN grade or primary tumour origin. Significant prognostic factors for survival were NEN grade/Ki67 index, ≥ 75% intrahepatic tumour load, the presence of extrahepatic disease and disease control rate according to RECIST 1.1.
conclusionSafety and efficacy of radioembolization in NEN patients was confirmed with a high disease control rate of 91% in progressive patients and alleviation of NEN-related symptoms in 79% of symptomatic patients. LEVEL OF EVIDENCE: 4.
Indexed as
Identifiers
30603975What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.